Contineum (CTNM) Q2 R&D Jumps 78%
Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotechnology company focused on developing treatments for serious diseases such as pulmonary fibrosis, multiple sclerosis, and depression, released its second quarter fiscal 2025 results on August 5, 2025. The most notable news in the earnings release was a wider GAAP net loss per share of $(0.62), missing the estimate of $(0.44). Research and development expenses (GAAP) saw a sharp rise as the company continued to advance its clinical pipeline. Management reported a robust cash position of $175.5 million as of June 30, 2025. Overall, the period reflected ongoing progress in pipeline development, but came with significantly higher spending and a continued absence of commercial revenue.
Source: Analyst estimates for the quarter provided by FactSet.
Contineum Therapeutics develops small molecule therapies for diseases with high unmet medical need. Its clinical programs focus on two main drug candidates: PIPE-791, an oral treatment being studied for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain; and PIPE-307, a selective M1R antagonist for use in depression and relapsing-remitting multiple sclerosis (RRMS). The company’s pipeline also includes earlier-stage assets like CTX-343, a peripherally restricted LPA1R antagonist.
Source Fool.com
